Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
Clinicians postulate that it may be interesting to combine the two IntraPeritoneal (IP)
treatments associated with a significant improvement of OC overall survival i.e.
cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) and
postoperative intraperitoneal chemotherapy (IPC) as an " intensive peritoneal " regimen in
the initial management of stages III-IVA ovarian cancers. Performing a postoperative IPC may
allow completing and extending the duration of the effect of HIPEC in decreasing the risk of
peritoneal recurrence. HIPEC may also allow administering an early IP treatment on the
residual microscopic disease during initial or interval surgery with an optimal access to the
intraperitoneal cavity. Postoperative IPC will extend the HIPEC effect on unsterilized
peritoneal microscopic residues with the aim of decreasing the risk of local recurrence.
Performing HIPEC before IPC could allow limiting the number of postoperative IP courses
needed. Nevertheless, this association questions its feasibility and tolerance, which should
both be assessed in a phase II trial. Clinicians propose to conduct this feasibility study
combining for the first time HIPEC with IPC as first-line treatment of ovarian cancer with
peritoneal carcinomatosis to perform a peritoneal intensification.